Pseudomembrane Removal for Post-RT Nasopharyngeal Necrosis

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorJiangxi Provincial Cancer Hospital

About this trial

This study aims to evaluate the effectiveness and safety of endoscopic nasopharyngeal pseudomembrane removal in reducing radiation-induced nasopharyngeal necrosis in patients with recurrent nasopharyngeal carcinoma who have received re-irradiation. This is a prospective, single-arm, multicenter interventional study. Participants with recurrent nasopharyngeal carcinoma who develop pseudomembrane reaction during or after re-irradiation will receive endoscopic pseudomembrane removal. Based on published literature, the 2-year incidence of radiation-induced nasopharyngeal necrosis after re-irradiation is approximately 40%. This study expects to reduce the incidence to 20%. The primary outcome measure is the 2-year incidence of nasopharyngeal necrosis after re-irradiation. Secondary outcome measures include: necrosis-free survival, overall survival, progression-free survival, local regional recurrence-free survival, distant metastasis-free survival, as well as safety and adverse events. A total of 40 participants will be enrolled from multiple hospitals in China.

Eligibility criteria

Qualifiers

Voluntarily sign the informed consent form.

Age between 18 and 80 years.

ECOG performance status ≤ 2.

Prior radical radiotherapy with total dose ≥ 66 Gy.

Disqualifiers

History of other malignancies within the past 5 years, except cured non-melanoma skin cancer or carcinoma in situ of the cervix.

Severe uncontrolled systemic diseases (e.g., uncontrolled infection, severe cardiovascular disease, uncontrolled diabetes).

Pregnant or breastfeeding women.

Known allergy to any equipment or medication used during endoscopy.

Trial design

Treatments tested in this trial

  • Endoscopic Nasopharyngeal Pseudomembrane Removal

Treatment groups

40 Participants
are divided into 1 treatment group

Locations

This trial has no locations